SAN DIEGO, March 1, 2017 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX) announced today that its fourth quarter and full year 2016 financial results will be released on Wednesday, March 15, 2017, after the market close. At 4:30 pm Eastern Time, Pfenex management will host a conference call to discuss the financial results and provide a business update. A press release outlining the financial results and business update will be publicly distributed prior to the call.
Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference Pfenex to access the call. A replay of the conference call will be available approximately one hour after the call until March 22, 2017. To access the teleconference replay please call 1-877-344-7529 (US) or 1-412-317-0088 (international) and enter the passcode 10102529. The conference call will also be available as a webcast. To access the webcast link please log on to www.pfenex.com.
Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (http://www.pfenex.com/), our investor relations website (http://pfenex.investorroom.com/), press releases, SEC filings, public conference calls, corporate Twitter account (https://twitter.com/pfenex), Facebook page (https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/), and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in order to achieve broad, non-exclusionary distribution of information to the public. We encourage our investors and others to review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.
About Pfenex Inc.
Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. The company's lead product candidates are PF582, a biosimilar candidate to Lucentis (ranibizumab), for the potential treatment of patients with retinal diseases and PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the potential treatment of patients with high fracture risk osteoporosis. Pfenex has leveraged its Pfēnex Expression Technology® platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics.
SOURCE Pfenex Inc.
For further information: Paul Wagner, Ph.D., Chief Financial Officer, (858) 352-4333, firstname.lastname@example.org